

Creo Medical Group plc

Significant Shareholders¹

Name of shareholder	Number of shares	Voting rights (%)
M&G Investments	47,503,836	11.52
Canaccord Genuity ²	35,384,613	8.58
Baillie Gifford	28,108,496	6.81
Hargreaves Lansdown, stockbrokers (EO)	27,116,004	6.57
River Global Investors	25,777,081	6.25
AXA Framlington Investment Managers	16,877,195	4.09
Amati Global Investors	13,549,536	3.28
Finance Wales Investments	13,126,727	3.18

Director Shareholdings (excluding options) as at 24 July 2025

Director	Number of shares	Voting rights (%)
Kevin T. Crofton	5,447,416	1.32
Ivonne Cantu	125,000	0.03
Craig Gulliford ³	1,686,194	0.41
Mr Richard Rees ⁴	3,069,963	0.74
Total	10,328,573	2.50

Percentage of AIM Securities not in public hands⁵ as at 24 July 2025: 20.77%

Issued Share Capital as at 24 July 2025: 412,473,319

¹ Information obtained from an analysis of Creo Medical's share register (dated 30 June 2025) undertaken on behalf of Creo Medical by EQ - RD:ID.

² Canaccord Genuity Wealth Management (Inst) – 31,500,000 - 7.64%; Canaccord Genuity Wealth Management (ND) - 3,884,613 - 0.94%.

³ Includes shares held by Craig Gulliford's wife and via the Creo Medical SIP.

⁴ Includes shares held by Richard Rees's wife, PCAs and via the Creo Medical SIP.

⁵ Shares not held in public hands as defined in the AIM Rules for Companies including shares held by related parties and their associates (as defined in the AIM Rules for Companies), shares held by trustees of the Company's employee share schemes and any substantial shareholders.